Our technology platform, INDUCE-seq®, detects and quantifies on- and off-targets supporting the development of safer cell and gene therapies.
Joined February 2021
- Tweets80
- Following33
- Followers87
- Likes8
Pinned Tweet
INDUCE-seq™ is a game changing #technology for development of advanced #therapies, but what is it?
Watch this video to learn how the platform precisely characterises breaks in the #genome, to inform the development of cutting edge therapeutics that are safer by design!🧪
We’re thrilled to launch the Catalyst program, our Early Access initiative that brings INDUCE-seq® directly into gene editing labs. Now, therapy developers can detect on- and off-target effects in days instead of months—accelerating development while ensuring safety.
By bringing INDUCE-seq® in-house, researchers gain faster insights, regulatory confidence, and real-time guide selection—a game-changer for gene editing safety.
Enrollment is limited—apply here: brokenstringbio.com/resource…
#GeneEditing #Biotech #CRISPR
Broken String Biosciences retweeted
Great to see Park-based @BrokenStringBio highlighted in the @Clarivate 'Companies to Watch: Next Generation Gene Editing' report.
You can download the full report here - ow.ly/zEkq50UCCNC
We are thrilled to be recognized for our role in shaping the future of genomic medicine by @pharmavoice. Our cutting-edge technologies provide vital insights for therapy developers, ensuring safety, efficacy, and scalability in the ever-evolving gene-editing landscape.
Read the full article here: lnkd.in/ewB-N3kY
This recognition inspires us to continue delivering impactful solutions for the next generation of genomic advancements. Read the full article here: lnkd.in/ewB-N3kY
We're thrilled to be featured in Clarivate’s Companies to Watch: Next Generation Gene Editing 2024 report!
clarivate.com/life-sciences-…
This coming week, our Director of Alliance Management and CCO will be attending the Cell & Gene Meeting on the Mesa in Phoenix, AZ, from October 7-9, 2024! #
We’re excited to engage in meaningful discussions & explore collaboration opportunities! See you there! #CGMESA24
ICYMI, our Co-founder and CSO, Simon Reed, Ph.D. discusses the current challenges in off-target gene editing and explores what the future holds for safer, more effective therapies.
To watch the webinar on-demand, you may register here: lnkd.in/ecNCjeWV #GeneEditing
Broken String Biosciences retweeted
Broken String Biosciences: Laurence Reid and Brad Crutchfield healthinvestor.co.uk/executi… #healthcare @BrokenStringBio @laurence_reid @Regeneron @ThirdRockV @Alnylam @10xGenomics @QIAGEN @illumina @BioRad
Broken String Biosciences retweeted
Park-based @BrokenStringBio has strengthened its Board with two new appointments - Laurence Reid, as Chairman, and Brad Crutchfield as Non-Executive Director.
Full story - ow.ly/YHKO50Tw3gR
Broken String Biosciences retweeted
Today @BrokenStringBio announced the appointments of Laurence Reid, as Chairman, and Brad Crutchfield as Non-Executive Director of its Board of Directors.
Read more: rb.gy/t801oi
#PressRelease #CellandGene
Exciting News! We’re delighted to welcome Laurence Reid, Ph.D. as Chairman and Brad Crutchfield as Non-Executive Director to our Board of Directors.
Their combined expertise in biotech and life sciences will be crucial as we continue to advance INDUCE-seq and drive growth in the cell and gene therapy industry. Read the full announcement here:
brokenstringbio.com/broken-s…
INDUCE-seq® can identify DNA double strand breaks without the need for DNA amplification, thus greatly increasing sensitivity and signal to noise ratio.
If you are looking for a highly sensitive assay for off-target detection in your gene-edited cell or gene therapy programs, simply message us at partnerships@brokenstringbio.com.
Broken String Biosciences retweeted
Broken String Biosciences Appoints Steve Becker as Chief Commercial Officer impactnews-wire.com/broken-s… @BrokenStringBio
We are thrilled to welcome Steve Becker as our Chief Commercial Officer. With over 30 years of experience in the global life sciences industry and a stellar track record, Steve will spearhead the commercialization of our pioneering DNA break-mapping platform, INDUCE-seq®.
Steve's leadership will be pivotal as we enhance our offerings in the cell and gene therapy market, ensuring transformative treatments become a safe reality for patients worldwide. Read more here: brokenstringbio.com/broken-s…